Canaccord Genuity set a $6.00 price objective on Palatin Technologies, Inc. (NYSEAMERICAN:PTN) in a research report released on Monday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

PTN has been the topic of a number of other research reports. Zacks Investment Research cut shares of Palatin Technologies from a buy rating to a hold rating in a report on Saturday, October 7th. Roth Capital set a $2.00 price objective on shares of Palatin Technologies and gave the company a buy rating in a research report on Sunday, October 29th.

Shares of Palatin Technologies (NYSEAMERICAN:PTN) opened at $0.78 on Monday. Palatin Technologies has a fifty-two week low of $0.29 and a fifty-two week high of $0.90.

Palatin Technologies (NYSEAMERICAN:PTN) last posted its quarterly earnings results on Monday, November 13th. The biopharmaceutical company reported $0.05 EPS for the quarter, missing the Zacks’ consensus estimate of $0.06 by ($0.01). The firm had revenue of $26.94 million for the quarter, compared to analysts’ expectations of $28.00 million. During the same quarter last year, the firm posted ($0.08) EPS.

ILLEGAL ACTIVITY NOTICE: “Canaccord Genuity Analysts Give Palatin Technologies, Inc. (PTN) a $6.00 Price Target” was reported by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/canaccord-genuity-analysts-give-palatin-technologies-inc-ptn-a-6-00-price-target/1707018.html.

An institutional investor recently bought a new position in Palatin Technologies stock. Russell Investments Group Ltd. purchased a new position in Palatin Technologies, Inc. (NYSEAMERICAN:PTN) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 225,246 shares of the biopharmaceutical company’s stock, valued at approximately $149,000. Russell Investments Group Ltd. owned 0.13% of Palatin Technologies at the end of the most recent quarter.

Palatin Technologies Company Profile

Palatin Technologies, Inc is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.

Receive News & Ratings for Palatin Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.